High mutation rate of RNA viruses requires manufacturers of live attenuated RNA virus vaccine to monitor each batch of vaccine for presence of "revertant" viruses with mutations that enable them to cause disease.  Each batch of oral poliovirus vaccine (OPV) must be tested for neurovirulence in animals and for the presence of revertants; this requires the use of many animals and is expensive  Previous techniques for detecting unstable sections of RNA virus genetic material by sequencing all genes of RNA viruses have been laborious, of limited sensitivity, or both.  CBER scientists have been working for over a decade to optimize and improve ways to monitor mutations in live RNA viruses
 Identified single nucleotide changes present at low levels  Identified areas of rapid change and areas of above-average stability in the genome  Demonstrated that MARSH microchips can be easily produced, making them more practical than industrially produced microchips
MARSH MAVR
 Showed that strain 14 from a person who contracted vaccine-associated paralytic poliomyelitis was a recombinant of Sabin types 1 and 2  Showed strain 11264 from a healthy child who had been in contact with the vaccine-associated case was a recombinant of Sabin types 2 and 3  Suggested that strain 11264 might have regained neurovirulent properties due to its very great divergence from a vaccine progenitor; subsequent testing in mice proved this was true.
MAVR demonstrated hybridization of Sabin and vaccine-derived polio virus strains (11264, 15763, 14829, 9457).
MAVR chips produced a hybridization image that graphically revealed recombination patterns and crossover regions. (A) WHO reference OPV used in MAPREC studies that represents a "passed" batch that has less than 0.7% of the revertant (B) US National Neurovirulence Reference for type 3 OPV (NC2), which represents a marginally acceptable vaccine (C) WHO reference OPV for MAPREC studies representing a "failed" batch that has 1.1% of revertants.
STEP THREE: MASSIVELY PARALLEL SEQUENCING
Encased beads are loaded into tiny reactor wells that contain sequencing enzymes--one bead per well.
MPS analysis of validated reference preparations
yielded results identical to those previously obtained using MAPREC. This suggests that MPS could replace MAPREC for lot release testing of OPV.
 MPS identified patterns of mutations near nucleotide 472 in three standardized samples of Sabin type 3 OPV.  The results suggest that MPS can be used to quantify the proportion of 472-U  472-C mutants, which determines the level of neurovirulence of the virus stock used to make OPV.
The CBER scientists reported for the first time that profiles of mutations in vaccine batches can be analyzed by MPS and used to ensure consistency in the manufacturing process-the cornerstone of vaccine safety.
THE FUTURE: The work performed for poliovirus may be applicable to evaluating consistency, safety and quality of other biologics. In-house use of MPS provides CBER expertise in this novel technology already being used by manufacturers, thus facilitating familiarity and readiness to evaluate MPSderived data submitted by sponsors in regulatory submissions.
